NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: COVID-19 Vaccination

Interventions: Bretovameran

Countries: South Korea

This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Korean subjects who are eligible for administration of Comirnaty Injection according to the locally authorized label
* Subjects with evidence of a personally signed and dated informed consent/assent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria:

* Subjects who involved in the contraindications of use indicated in the locally authorized label
* Subjects with a history of hypersensitivity to any ingredients of this product or this product
* Any subjects (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information

Locations (1)

Seoul, South Korea